Clinical trial
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00138840 · Synta Pharmaceuticals Corp., Industry · Completed
Key facts
| NCT number | NCT00138840 |
|---|---|
| Title | Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, for the Induction of Clinical Response in Patients With Crohn's Disease |
| Lead sponsor | Synta Pharmaceuticals Corp., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | STA-5326 mesylate |
| Enrollment | 282 |
| Start date | Aug 1, 2005 |
| First posted | Aug 30, 2005 |
| Last update posted | Dec 4, 2008 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: